MORE►
Nanoscope
[Image: S-S-S/istockphoto]
Patented: Nanoscope Therapeutics’ Optogenetic Vision Restoration and More North Texas Inventive Activity
by Dallas Innovates | Staff Report | Dec 10, 2025
Dallas-Fort Worth ranked No. 9 for patent activity out of 250 metros for the week of Nov. 4 with a total of 156 patents granted.
by Lance Murray |
May 17, 2024
Khandan Baradaran, PhD, was most recently VP of regulatory CMC at Ultragenyx Pharmaceutical, a biopharmaceutical company involved in the research and development of novel products for the treatment of rare and ultra-rare genetic diseases.
MORE►
by Lance Murray |
Apr 26, 2024
Dallas-based Nanoscope said Dr. Allen C. Ho will help define the strategy of developing its gene mutation-agnostic therapies. Ho is attending surgeon and director of retina research at Wills Eye Hospital and co-director of the Wills Eye Hospital Retina Service.
MORE►
by Lance Murray |
Dec 8, 2023
Splendorio's more than 30 years of experience have been marked by extensive executive leadership in the ophthalmic industry, and he will support Nanoscope in reaching its strategic vision, the company said.
MORE►
DI People: Dave & Busters, Fujitsu, Keurig Dr Pepper, Aurora Innovation, DHA, and More Make Leadership Moves
by Lance Murray | Apr 8, 2022
In this week's roundup of hires, promotions, and accolades in North Texas, you'll also find news from Firehouse, Enseo, Cambium Learning, D Magazine, Lear Investment Management, Spacee, Envy Gaming, 5Q, Stream Realty Partners, Nanoscope, Crossplane Capital, Improving, TimelyMD and more.
MORE►
by Alex Edwards |
Sep 14, 2021
The Bedford-based biotech will use the capital from the National Eye Institute of the National Institutes of Health to advance its gene therapy that treats age-related macular degeneration.
Earlier this summer, Nanoscope Therapeutics announced it successfully treated 11 patients who were blinded by advanced retinitis pigmentosa.
Earlier this summer, Nanoscope Therapeutics announced it successfully treated 11 patients who were blinded by advanced retinitis pigmentosa.
MORE►
by Lauren Hawkins |
Jul 21, 2020
Nanoscope Therapeutics, a TechFW client, has closed an over-subscribed Series A funding round for its leading work on retinas, which could enable the blind to see.
In addition, Nanoscope has named Al Guillem as Chairman of the Board. Guillem (pictured below) was part of TechFW's greatest success story when ZS Pharma, a company he co-founded, was purchased by AstraZeneca for $2.7 billion.
In addition, Nanoscope has named Al Guillem as Chairman of the Board. Guillem (pictured below) was part of TechFW's greatest success story when ZS Pharma, a company he co-founded, was purchased by AstraZeneca for $2.7 billion.
MORE►
by Alex Edwards |
Jun 1, 2020
DesignPlex Biomedical was given a royalty-free license by NASA to commercialize a new ventilator for coronavirus patients. Nanoscope Technologies got more than $2 million from the National Eye Institute to advance its gene therapy treatment.
MORE►
